What Ocrevus treats
Ocrevus (ocrelizumab) is a biologic medication used to treat multiple sclerosis (MS) in both its relapsing and primary progressive forms. It is designed to reduce the frequency of relapses and slow disease progression by targeting and depleting specific immune cells involved in the inflammatory process of MS. Ocrevus offers significant benefits for managing symptoms and improving the quality of life for patients with MS.
Benefits of Ocrevus
Patients using Ocrevus often experience significant benefits, including a reduction in the frequency of MS relapses, slower progression of disability, and improved overall disease management. For those with primary progressive MS, Ocrevus can help slow the rate of progression and provide meaningful relief from symptoms. The biannual infusion schedule offers a convenient treatment regimen for ongoing management of MS.
Possible Side Effects of Ocrevus
While Ocrevus is generally well-tolerated, some patients may experience side effects, including infusion-related reactions such as fever, chills, and rash, as well as infections. Other potential side effects include headaches, fatigue, and gastrointestinal issues. Serious side effects can include an increased risk of infections, including serious infections like hepatitis B reactivation. It’s important to monitor your health closely and report any unusual symptoms to your healthcare provider.
How infusion works at Prime
Ocrevus is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Ocrevus, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Ocrevus Work?
Ocrevus works by targeting and depleting CD20-positive B cells, a type of immune cell that plays a crucial role in the inflammatory process associated with MS. By binding to CD20, Ocrevus helps to reduce the number of these cells, thereby decreasing inflammation, slowing disease progression, and reducing the frequency of MS relapses. Ocrevus is administered through intravenous infusion, with the first dose given as two separate infusions followed by subsequent infusions every six months.
Who is Ocrevus For?
Ocrevus is suitable for adults with relapsing forms of MS (including relapsing-remitting MS) and those with primary progressive MS. It is prescribed for patients who have not responded adequately to other MS therapies or who are looking for a treatment to help manage their symptoms and slow disease progression. Ocrevus is recommended for individuals with active disease as well as those with progressive forms of MS.